 |
January 9, 2012
GENERIC PRESCRIPTION MEDICINES SAVED CANADA’S HEALTH-CARE SYSTEM
$26-BILLION OVER PAST FIVE YEARS
|
|
The use of generic prescription medicines has saved Canada’s health-care system nearly $26-billion since 2007, according to an analysis of Canadian retail prescription drug sales information released today by the Canadian Generic Pharmaceutical Association (CGPA). | read more... |
|
October 17, 2011
Statement from the Canadian Generic Pharmaceutical Association (CGPA)
Regarding Shortages of Prescription Medicines
|
|
“Millions of Canadians rely on generic prescription medicines daily for their pharmaceutical treatments and Canada’s generic pharmaceutical manufacturers take the responsibility of providing high-quality, lower-cost generic pharmaceutical products for Canadian patients extremely seriously. | read more... |
|
October 11, 2011
NEW REPORT: ADOPTION OF EU’S PHARMACEUTICAL PROPOSALS WOULD MEAN
CANADA LOSES OUT ON FAST-GROWING GENERIC INDUSTRY INVESTMENTS
|
|
Canada could face a loss of jobs and investment in its R&D intensive and fast-growing generic pharmaceutical industry if the European Union’s pharmaceutical intellectual property proposals in the current Canada-EU trade negotiations are adopted, according to a new report released today. | read more... |
|
July 15, 2011
CGPA CONGRATULATES TEVA CANADA ON $56-MILLION INVESTMENT TO EXPAND HIGH POTENCY MANUFACTURING CENTRE OF EXCELLENCE
|
|
The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the joint announcement today by Teva Canada and the Ontario Ministry of Economic Development and Trade of the expansion of Teva Canada’s High Potency Manufacturing Centre of Excellence in Stouffville, Ontario. | read more... |
|
July 14, 2011
Canada’s IP Regime for Pharmaceuticals Reaffirmed
as One of the Most Aggressive and Extensive in the World
|
|
The Supreme Court of Canada today said it would not hear the appeals of CGPA and generic drug maker Apotex regarding changes made to Canada’s data protection regime for pharmaceuticals in 2006. The Court did not provide its reasons as per its custom. | read more... |
|
June 23, 2011
Pharmaceutical R&D Spending Drops to Lowest Level Since 1988
|
|
Only 6.9% of brand-name drug companies’ Canadian sales revenues
spent on research and development
Research and development spending in Canada by brand-name drug companies has dropped to its lowest level since 1988, according to the latest annual report of the Patented Medicine Prices Review Board (PMPRB).
| read more... |
|
June 7, 2011
EU PROPOSALS IN TRADE NEGOTIATIONS WOULD WIPE OUT SAVINGS FROM ONTARIO DRUG REFORMS
|
|
Changes to Canada’s drug patent system proposed by the European Union (EU) would wipe out the savings from Ontario government’s drug reforms, Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), said today on the one-year anniversary of Ontario’s drug system changes. | read more... |
|
June 6, 2011
CGPA Statement Regarding Federal Budget 2011
|
|
The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding Federal Budget 2011. | read more... |
|
May 30, 2011
Canada's Intellectual Property Protection for Pharmaceuticals Stronger In Many Ways than EU and US
|
|
Canada's intellectual property system for pharmaceuticals is already stronger than that in any other industrial sector in Canada, and is in many ways stronger than pharmaceutical IP in the European Union (EU) and United States (US), according to a new report by Edward M. Iacobucci, the Osler Chair in Business Law at the University of Toronto's Faculty of Law. | read more... |
|
May 16, 2011
Pharmascience investment in Montreal confirms strength of generic pharmaceutical industry in Quebec
|
|
The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) regarding today’s announcement by Pharmascience of its $38 million investment in Montreal, which will result in new laboratories, increased manufacturing capacity, and the creation of 180 jobs. | read more... |
|
May 5, 2011
Release of Canadian Prescription Drug Sales Information
Highlights Increasing Value of Generic Medicines
|
|
The release of Canadian prescription drug sales information by the Canadian Institute for Health Information (CIHI) demonstrates that generic prescription medicines are making an even greater contribution to sustainable health care in Canada, Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), said today. | read more... |
|
May 2011
Statement from the Canadian Generic Pharmaceutical Association (CGPA)
Regarding Shortages of Prescription Medicines
|
|
The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding media reports of prescription drug shortages in Canada. | read more... |
|
March 31, 2011
CGPA Statement Regarding Big Pharma Analysis of Economic Impact Assessment
of European Union’s Proposed Pharmaceutical IP Provisions under CETA
|
|
The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), about the report released today by brand-name drug companies | read more... |
|
March 29, 2011
Release of Canadian Prescription Drug Sales Information
Highlights Increasing Value of Generic Medicines
|
|
The release of final 2010 Canadian prescription drug sales information by IMS Brogan shows that generic prescription medicines have never offered greater value for Canadians, Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) said today.
| read more... |
|
March 22, 2011
CGPA Statement Regarding Federal Budget 2011
|
|
The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding Federal Budget 2011:
| read more... |
|
March 3, 2011
CGPA Statement Regarding Bill C-393, proposed changes
to Canada’s Access to Medicines Regime
|
|
The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding Bill C-393, which seeks to make changes to Canada’s Access to Medicines Regime (CAMR):
| read more... |
|
February 7, 2011
NEW STUDY: PROPOSALS IN CANADA-EU TRADE NEGOTIATIONS WOULD ADD $2.8 BILLION ANNUALLY TO CANADA’S PRESCRIPTION DRUG BILL |
|
Changes to Canada’s drug patent system proposed by the European Union (EU) would add nearly $3-billion annually to Canada’s prescription drug bill according to a new study by two of Canada’s top academics on pharmaceutical policy. | read more... |
|
January 24, 2011
BARRY FISHMAN OF TEVA CANADA ELECTED CHAIR OF CANADIAN GENERIC PHARMACEUTICAL ASSOCIATION |
|
The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the election of Mr. Barry Fishman, President and Chief Executive Officer of Teva Canada, as Chair of CGPA, and Mr. Mario Deschamps, President and Chief Operating Officer of Pharmascience, as Vice Chair of CGPA.| read more... |
|
January 19, 2011
Statement from the Canadian Generic Pharmaceutical Association
Regarding Canadian Chamber of Commerce Report
on Intellectual Property in the Pharmaceutical Sector |
|
The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the report on intellectual property in the pharmaceutical sector released today by the Canadian Chamber of Commerce:| read more... |
|
December 15, 2010
Retail Prices of Generic Drugs Reduced Dramatically in Canada |
|
Now that retail prices for generic prescription medicines have been dramatically reduced across Canada, public and private drug plans must take advantage of these savings by increasing their use of cost-saving generics, Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), said in response to new reports released today by the Patented Medicine Prices Review Board (PMPRB). | read more... |
|
September 27, 2010
Generic Pharmaceutical Industry Supports Health Council of Canada Findings on Drug Companies’ Influence on Prescribing |
|
Canada’s generic pharmaceutical industry supports recommendations in the report released today by the Health Council of Canada urging governments to take action to offset the marketing of brand-name drugs to health-care professionals. | read more... |
|
August 27, 2010
Generic Pharmaceutical Industry Supports Ontario’s Narcotics Strategy |
|
Canada’s generic pharmaceutical industry strongly supports efforts announced today by the Government of Ontario to curb the abuse of prescription narcotics and controlled substances. | read more... |
|
August 17, 2010
Statement from the Canadian Generic Pharmaceutical Association (CGPA) Regarding Shortages of Prescription Medicines |
|
The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding media reports of prescription drug shortages in Canada: | read more... |
|
June 24, 2010
Pharmaceutical R&D Spending Drops to Lowest Level in 20 Years |
|
Only 7.5% of brand-name drug companies’ Canadian sales revenues spent on research and development
Research and development spending in Canada by brand-name drug companies has dropped to its lowest level in 20 years, according to the latest annual report of the Patented Medicine Prices Review Board (PMPRB).
read more... |
|
April 8, 2010
Statement from the Canadian Generic Pharmaceutical Association
Regarding Changes to Ontario's Drug Systems |
|
The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding yesterday’s announcement by the Honourable Deb Matthews, Minister of Health and Long-Term Care, regarding changes to Ontario’s Drug Systems:| read more... |
|
April 6, 2010
Matching US Generic Drug Use Would Save Canada $1.6-Billion |
|
Canada continues to lag behind United States in use of lower-cost generic medicines
If the use of lower-cost generic medicines in Canada increased to levels in the United States, Canadians would save and additional $1.6-billion in prescription drug costs in the first year alone. | read more... |
|
March 25, 2010
Statement from the Canadian Generic Pharmaceutical Association
Regarding the 2010 Ontario Budget |
|
| A statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the 2010 Ontario Budget: | read more... |
|
February 10, 2010
CGPA demands withdrawal of Fédération des médecins spécialistes du Québec (Quebec Federation of Specialized Physicians) TV commercial |
|
| The Canadian Generic Pharmaceutical Association (CGPA) is demanding that media and FMSQ immediately withdraw a TV ad by the Fédération des médecins spécialistes du Québec dealing with generic medication. “We are in no way required to take part in the specialized physicians’ negotiations with government,” explained CGPA President Jim Keon. | read more... |
|
| |
|
TOP |
| |
|
|
